Dr Sandip Prasad speaks to ecancer about the results of the phase 3 ATLAS and ENVISION studies regarding the treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with UGN-102.

UGN-102 is being evaluated in two phase three clinical trials, ATLAS and ENVISION, for treating bladder cancer.

ATLAS compares UGN-102 to standard treatment for low-grade, intermediate-risk, non-muscle invasive bladder cancer, while ENVISION focuses on recurrent cases.

Initial results show similar response rates at three months, but UGN-102 offers better durability at 12 months, marking a significant advancement in bladder cancer management.